Novogen Announces Collaboration Agreement to Bring Cosmetic Products to Market
| Source: Novogen
NEW CANAAN, CT and SYDNEY, AUSTRALIA--(Marketwire - October 25, 2007) - Novogen Limited
(NASDAQ : NVGN ) announced today a collaboration agreement to develop new
cosmetic applications. The finished products will be manufactured and
distributed by a leading cosmetics company, worldwide.
The partnership matches Novogen's expertise in the identification,
preparation, analysis and production of compounds with the expertise of a
leading global beauty company.
Preliminary research shows that a number of Novogen's compounds have
potential in various cosmetic applications. Novogen's patent position is
an added benefit to the cosmetics industry at large.
Novogen retains full rights to wound care applications, treatment of burned
tissue, hair growth treatments, prescription treatment of skin diseases or
skin cancer, injectables of antidote formulations, or trans-dermal delivery
of pharmaceutical formulations.
Christopher Naughton, CEO of Novogen, said, "We are proud to be part of the
vision, research, and dedication of the cosmetics industry to skin care and
look forward to a fruitful partnership."
About Novogen Limited
Novogen Limited (NASDAQ : NVGN ) is an Australian biotechnology company which
has patented isoflavone technology for the treatment and prevention of
degenerative diseases and disorders. Over the past ten years, Novogen has
conducted the largest and most comprehensive isoflavone clinical testing
programs in the world. Novogen is involved in drug discovery and product
development for disorders that are commonly associated with aging and
coordinates an international clinical research and development program with
external collaborators, hospitals and universities. For more information,
visit www.novogen.com.
Statements included in this press release that are not historical in nature
are "forward-looking statements" within the meaning of the "safe harbor"
provisions of the Private Securities Litigation Reform Act of 1995. You
should be aware that our actual results could differ materially from those
contained in the forward-looking statements, which are based on
management's current expectations and are subject to a number of risks and
uncertainties, including, but not limited to, our failure to successfully
commercialize our product candidates; costs and delays in the development
and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability to
maintain or enter into, and the risks resulting from our dependence upon,
collaboration or contractual arrangements necessary for the development,
manufacture, commercialization, marketing, sales and distribution of any
products; competitive factors; our inability to protect our patents or
proprietary rights and obtain necessary rights to third party patents and
intellectual property to operate our business; our inability to operate our
business without infringing the patents and proprietary rights of others;
general economic conditions; the failure of any products to gain market
acceptance; our inability to obtain any additional required financing;
technological changes; government regulation; changes in industry practice;
and one-time events. We do not intend to update any of these factors or to
publicly announce the results of any revisions to these forward-looking
statements.